BIOCRYST PHARMACEUTICALS, INC. Operating Lease, Weighted Average Discount Rate, Percent
BIOCRYST PHARMACEUTICALS, INC. (BCRX) had Operating Lease, Weighted Average Discount Rate, Percent of 10.10% as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Notes › Leases
us-gaap:OperatingLeaseWeightedAverageDiscountRatePercent · last filed 2026-08-05
- 2026-06-30: Operating Lease, Weighted Average Discount Rate, Percent 10.10%.
- 2026-03-31: Operating Lease, Weighted Average Discount Rate, Percent 10.06%.
- 2025-12-31: Operating Lease, Weighted Average Discount Rate, Percent 10.70%.
- 2025-09-30: Operating Lease, Weighted Average Discount Rate, Percent 10.71%.
| Period end | Operating Lease, Weighted Average Discount Rate, Percent | Operating Lease, Weighted Average Discount Rate, Percent as first filed |
|---|---|---|
| 2026-06-30 | 10.10% 10-Q · filed 2026-08-05 | |
| 2026-03-31 | 10.06% 10-Q · filed 2026-05-06 | |
| 2025-12-31 | 10.70% 10-Q · filed 2026-08-05 | |
| 2025-09-30 | 10.71% 10-Q · filed 2025-11-04 | |
| 2025-06-30 | 10.71% 10-Q · filed 2025-08-05 | |
| 2025-03-31 | 10.92% 10-Q · filed 2025-05-06 | |
| 2024-12-31 | 10.91% 10-K · filed 2026-02-26 | |
| 2024-09-30 | 10.91% 10-Q · filed 2024-11-05 | |
| 2024-06-30 | 10.90% 10-Q · filed 2024-08-06 | |
| 2024-03-31 | 10.89% 10-Q · filed 2024-05-07 | |
| 2023-12-31 | 10.88% 10-K · filed 2025-02-25 | |
| 2023-09-30 | 10.00% 10-Q · filed 2023-11-08 | |
| 2023-06-30 | 10.30% 10-Q · filed 2023-08-07 | |
| 2023-03-31 | 10.80% 10-Q · filed 2023-05-08 | |
| 2022-12-31 | 12.54% 10-K · filed 2024-02-27 | 10.96% 10-K · filed 2023-02-27 |
| 2022-09-30 | 10.90% 10-Q · filed 2022-11-04 | |
| 2022-06-30 | 10.90% 10-Q · filed 2022-08-05 | |
| 2021-12-31 | 11.20% 10-K · filed 2023-02-27 | |
| 2021-09-30 | 12.50% 10-Q · filed 2021-11-04 | |
| 2021-06-30 | 12.80% 10-Q · filed 2021-08-09 | |
| 2021-03-31 | 10.36% 10-Q · filed 2022-05-09 | 12.80% 10-Q · filed 2021-05-07 |
| 2020-12-31 | 12.70% 10-K · filed 2021-03-01 | |
| 2020-09-30 | 12.80% 10-Q · filed 2020-11-06 | |
| 2020-06-30 | 12.70% 10-Q · filed 2020-08-07 | |
| 2020-03-31 | 12.70% 10-Q · filed 2020-05-11 | |
| 2019-12-31 | 12.70% 10-K · filed 2020-03-13 | |
| 2019-09-30 | 12.60% 10-Q · filed 2019-11-08 | |
| 2019-06-30 | 12.60% 10-Q · filed 2019-08-08 | |
| 2019-03-31 | 12.60% 10-Q · filed 2019-05-09 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| Vir Biotechnology, Inc. (VIR) | United States | $1.814B | -6.85 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| NOVAVAX INC (NVAX) | United States | $1.748B | -6.26 |
| Hemab Therapeutics Holdings, Inc. (COAG) | United States | $1.672B | |
| Immunocore Holdings plc (IMCR) | $1.613B | -90.43 |